Market Snapshot
S&P Futures
3,819
Dow Futures
30,822
Nasdaq Futures
11,785
Ayala Pharmaceuticals, Inc. (AYLA) stock rallied over 1.83% intraday to trade at $1.11 a share on NASDAQ. The stock opened with a loss of -0.00% at $1.12 and touched an intraday high of $1.22, rising 1.83% against the last close of $1.09. The stock went to a low of $1.1 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-06 | $1.12 | $1.22 | $1.1 | $1.12 | 82,257 |
2022-07-05 | $1.11 | $1.15 | $1.06 | $1.09 | 75,900 |
2022-07-01 | $1.04 | $1.12 | $1.03 | $1.113 | 8,800 |
2022-06-30 | $1.007 | $1.106 | $0.99 | $1.09 | 11,600 |
2022-06-29 | $1.12 | $1.12 | $0.956 | $0.99 | 75,000 |
2022-06-28 | $1.08 | $1.12 | $1.08 | $1.1 | 13,300 |
2022-06-27 | $1.2 | $1.21 | $1.09 | $1.11 | 19,500 |
2022-06-24 | $1.306 | $1.31 | $1.07 | $1.07 | 27,900 |
2022-06-23 | $1.28 | $1.33 | $1.25 | $1.25 | 9,600 |
2022-06-22 | $1.23 | $1.3 | $1.23 | $1.274 | 15,200 |
Employees-
Beta-
Sales or Revenue3.51 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) stock price is $1.11 as of the last check on Wednesday, July 6. During the trading session, AYLA stock reached the peak price of $1.22 while $1.1 was the lowest point it dropped to.
The NASDAQ listed AYLA is part of Biotechnology industry that operates in the broader Health Care sector. Ayala Pharmaceuticals, Inc. , a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers.
Dr. Roni Mamluk M.D., Ph.D.
Pres, CEO & Director
Mr. Yossi Maimon CPA, M.B.A., CPA, MBA
CFO, Sec. & Treasurer
Dr. Gary B. Gordon M.D., Ph.D.
Chief Medical Officer
Ms. Irit Klipper Avni M.A.
VP of HR
AYLA stock traded closed the last session at $1.12, which is $0.02 or 1.83% lower than its previous close of $1.09. AYLA's current trading price is 16.08% lower than its 52-week high of $14.95 where as its distance from 52-week low of 0.96% is -92.58%.
Number of AYLA employees currently stands at -. AYLA operates from 4 Oppenheimer Street, Rehovot 7670104, Israel.
Official Webiste of $AYLA is: https://www.ayalapharma.com
AYLA could be contacted at AYLA operates from 4 Oppenheimer Street, Rehovot 7670104, Israel, or at phone #857 444 0553 and can also be accessed through its website.
AYLA stock volume for the day was 84,262 shares while in the previous session number of AYLA shares traded was 82,257 . The average number of AYLA shares traded daily for last 3 months was 58.56 Thousands.
The percentage change in AYLA stock occurred in the recent session was 1.83% while the dollar amount for the price change in AYLA stock was $0.02.
In the recent session, the day high for AYLA stock was $1.22 while the low for AYLA stock touched on the day was $1.1.
The market value of AYLA currently stands at 15.36 Million with its latest stock price at $1.11 and 15.3 Million of its shares outstanding.